Who are CLBS12's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, IL-2 pre-treated CD19 cells, ACP, MC, Cord blood, Licartin and CIK.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/clbs12.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

CLBS12 — Competitive Intelligence Brief

CLBS12 (CLBS12) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cell therapy. Area: Cardiovascular.

phase 2 cell therapy Cardiovascular Biologic Live · refreshed every 30 min

Target snapshot

CLBS12 (CLBS12) — Lisata Therapeutics, Inc.. CLBS12 is a cell therapy product that aims to repair or replace damaged heart tissue.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CLBS12 TARGET	CLBS12	Lisata Therapeutics, Inc.	phase 2	cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
IL-2 pre-treated CD19 cells	IL-2 pre-treated CD19 cells	jiangjingting	marketed	Adoptive cell therapy	CD19
ACP	ACP	Istituto Ortopedico Rizzoli	marketed	Cell therapy / Regenerative medicine product
MC	MC	Aivita Biomedical, Inc.	marketed	Mesenchymal stem cell therapy
Cord blood	Cord blood	New York Medical College	marketed	Hematopoietic stem cell therapy
Licartin and CIK	Licartin and CIK	Tianjin Medical University Cancer Institute and Hospital	marketed	Monoclonal antibody (Licartin); Adoptive cell therapy (CIK)	HAb18G/CD147 antigen (Licartin); Multiple (CIK cells)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (cell therapy class)

Lisata Therapeutics, Inc. · 2 drugs in this class
Diakonos Oncology Corporation · 1 drug in this class
Lineage Cell Therapeutics, Inc. · 1 drug in this class
Steminent Biotherapeutics Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CLBS12 — Competitive Intelligence Brief. https://druglandscape.com/ci/clbs12. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab